The Hygiology Post ® has been presenting information about a company formerly called Senesco Technologies which recently merged and rebranded to Sevion Therapeutics that seems to have much potential to help many people. As a matter of disclosure : The author continues to be a current shareholder in the company.
Earlier this month the article “Sevion Therapeutics to Present at 2015 BIO International Convention” (https://www.seviontherapeutics.com/sevion-therapeutics-to-present-at-2015-bio-international-convention/; obtained on 6-14-2014) began the following way:
“SAN DIEGO, CA – June 3, 2015 – Sevion Therapeutics, Inc. (‘Sevion’ or the ‘Company’)(OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Miguel de los Rios, Ph.D., Vice President of Research and Development, will present an overview of the Company’s technology and programs at the 2015 BIO International Convention in Philadelphia, PA on June 16, 2015. ‘We are excited to share our discoveries and progress with the biotechnology community at BIO 2015, particularly our progress in identifying and developing antibodies against high-value difficult targets like ion channels and GPCRs,’ noted Dr. de los Rios. The Company employs unique strategies to discover antibodies against multipass membrane proteins, including utilization of a novel cow antibody scaffold which was featured on the cover of Cell in 2013.”
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2015 The Hygiology Post ®